Allogene Therapeutics, Inc. ALLO
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 53 cents this year.
The 8-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | ◌ |
| Operating income $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| EBITDA $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| Free cash flow $B | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.0 |
| EPS, diluted $ | −0.87 | −1.32 | −2.09 | −2.38 | −1.34 | −2.63 | −1.83 | −7.31 |
| Dividend / sh $ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — |
| ROE % | −53.4 | −55.1 | −55.5 | −42.8 | −18.8 | −38.5 | −27.7 | −30.1 |
| Shares out B | 0.23 | 0.21 | 0.17 | 0.14 | 0.14 | 0.14 | 0.00 | 0.00 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018.